IP Verse

Tofacitinib Oral Sustained Release Dosage Forms

Patent No. EP2968155 (titled "Tofacitinib Oral Sustained Release Dosage Forms") was filed by Pfizer on Mar 12, 2014. The application was issued on Mar 3, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKDec 3, 2021ELKINGTON AND FIFE
KRAUS & LEDERER PARTGMBBDec 3, 2021KRAUS & LEDERER PARTGMBB
STADA ARZNEIMITTELDec 3, 2021HAMM & WITTKOPP
TEVA PHARMACEUTICALSDec 3, 2021D YOUNG
GREINERDec 2, 2021GREINER
AERANov 30, 2021-

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2968155

PFIZER
Application Number
EP14726410A
Filing Date
Mar 12, 2014
Status
Revoked
Sep 26, 2025
Publication Date
Mar 3, 2021
External Links
Slate, Register , Google Patents